196 related articles for article (PubMed ID: 25982801)
1. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
Liss MA; Xu J; Chen H; Kader AK
Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
[TBL] [Abstract][Full Text] [Related]
2. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
3. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
Kader AK; Liss MA; Trottier G; Kim ST; Sun J; Zheng SL; Chadwick K; Lockwood G; Xu J; Fleshner NE
Urology; 2015 Jan; 85(1):165-70. PubMed ID: 25530379
[TBL] [Abstract][Full Text] [Related]
4. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
5. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
6. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
7. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
8. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
9. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
11. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort.
Srivastava P; Kapoor R; Mittal RD
Gene; 2013 Nov; 530(2):273-7. PubMed ID: 23872201
[TBL] [Abstract][Full Text] [Related]
12. Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
Shoag J; Mittal S; Halpern JA; Scherr D; Hu JC; Barbieri CE
Eur Urol; 2016 Jul; 70(1):2-5. PubMed ID: 27166670
[TBL] [Abstract][Full Text] [Related]
13. Utility of incorporating genetic variants for the early detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
[TBL] [Abstract][Full Text] [Related]
14. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
[TBL] [Abstract][Full Text] [Related]
15. Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels.
Licastro F; Bertaccini A; Porcellini E; Chiappelli M; Pernetti R; Sanguedolce F; Marchiori D; Martorana G
Anticancer Res; 2008; 28(1B):395-9. PubMed ID: 18383875
[TBL] [Abstract][Full Text] [Related]
16. Patterns of prostate-specific antigen (PSA) testing in Australian men: the influence of family history.
McDowell ME; Occhipinti S; Gardiner RA; Chambers SK
BJU Int; 2012 Apr; 109 Suppl 3():64-70. PubMed ID: 22458497
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.
Danforth KN; Hayes RB; Rodriguez C; Yu K; Sakoda LC; Huang WY; Chen BE; Chen J; Andriole GL; Calle EE; Jacobs EJ; Chu LW; Figueroa JD; Yeager M; Platz EA; Michaud DS; Chanock SJ; Thun MJ; Hsing AW
Carcinogenesis; 2008 Mar; 29(3):568-72. PubMed ID: 17999989
[TBL] [Abstract][Full Text] [Related]
18. THADA gene polymorphism and prostate cancer risk: a meta-analysis.
Zhao F; Xu Y; Yang K; Liu M; Wei D; Zhang Y; Shi X; Yang F; Wang X; Liang S; Zhao C; Chen X; Sun L; Zhu X; Wang N; Hui J; Zhang Y; Zhu L; Yang Y; Tang L; Wang J; Yang Z
Oncol Res Treat; 2014; 37(3):106-10. PubMed ID: 24685913
[TBL] [Abstract][Full Text] [Related]
19. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.
Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippmann SM; Parnes HL; Dluzniewski PJ; Isaacs WB; De Marzo AM; Drake CG; Platz EA
Prostate; 2015 Sep; 75(13):1403-18. PubMed ID: 26047319
[TBL] [Abstract][Full Text] [Related]
20. KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland.
Seppälä EH; Autio V; Duggal P; Ikonen T; Stenman UH; Auvinen A; Bailey-Wilson JE; Tammela TL; Schleutker J
Eur Urol; 2007 Oct; 52(4):1076-81. PubMed ID: 17125911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
